NewAmsterdam Pharma (NASDAQ:NAMS) Insider Juliette Berangere Audet Buys 1,104 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) insider Juliette Berangere Audet bought 1,104 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were acquired at an average cost of $15.70 per share, with a total value of $17,332.80. Following the completion of the purchase, the insider now owns 1,104 shares in the company, valued at approximately $17,332.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NewAmsterdam Pharma Stock Up 0.8 %

NASDAQ NAMS opened at $17.43 on Thursday. NewAmsterdam Pharma has a 1-year low of $5.63 and a 1-year high of $26.35. The business has a 50 day moving average price of $16.47 and a 200 day moving average price of $18.91.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.08. The firm had revenue of $2.28 million during the quarter, compared to analysts’ expectations of $2.20 million. On average, analysts predict that NewAmsterdam Pharma will post -2.06 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Needham & Company LLC assumed coverage on NewAmsterdam Pharma in a research note on Wednesday, August 28th. They set a “buy” rating and a $36.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $33.80.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma in the 2nd quarter valued at approximately $38,000. Sei Investments Co. increased its position in NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after buying an additional 8,087 shares in the last quarter. Wolverine Asset Management LLC increased its position in NewAmsterdam Pharma by 117.7% during the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after buying an additional 8,394 shares in the last quarter. Rosalind Advisors Inc. purchased a new position in NewAmsterdam Pharma during the second quarter worth $194,000. Finally, Yarbrough Capital LLC purchased a new position in NewAmsterdam Pharma during the first quarter worth $567,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.